Repligen/RGEN
13:30
14:25
15:15
16:10
17:00
1D1W1MYTD1YMAX
About Repligen
Repligen Corp is a global life sciences company. It develops and commercializes innovative bioprocessing technologies and systems that increase efficiencies and flexibility in the process of manufacturing biological drugs. The company's customers include life science companies, global biopharmaceutical companies, and contract manufacturers worldwide. Repligen markets its products globally through a direct commercial organization in the U.S., Europe, and Asia, as well as through strategic partners in select markets. The majority of the company's revenue is generated in North America.
Ticker
RGEN
Sector
Healthcare
Trading on
NASDAQ
Industry
Life Sciences Tools and Services
Headquarters
Waltham, United States
Employees
-
Website
www.repligen.com
Repligen Metrics
BasicAdvanced
$6.7B
Market cap
453.98
P/E ratio
$0.26
EPS
1.03
Beta
-
Dividend rate
Price and volume
Market cap
$6.7B
Beta
1.03
Financial strength
Current ratio
6.354
Quick ratio
5.027
Long term debt to equity
33.415
Total debt to equity
37.437
Interest coverage (TTM)
1.75%
Management effectiveness
Return on assets (TTM)
0.60%
Return on equity (TTM)
0.76%
Valuation
Price to earnings (TTM)
453.98
Price to revenue (TTM)
11.03
Price to book
3.4
Price to tangible book (TTM)
11.22
Price to free cash flow (TTM)
61.16
Growth
Revenue change (TTM)
-21.90%
Earnings per share change (TTM)
-91.02%
3-year revenue growth
11.95%
3-year earnings per share growth
-43.35%
What the Analysts think about Repligen
Analyst Ratings
Majority rating from 13 analysts.
Repligen Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$151M
-2.83%
Net income
$2M
-107.87%
Profit margin
1.32%
-108.09%
Repligen Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
$0.53
$0.23
$0.33
$0.28
-
Expected
$0.48
$0.17
$0.33
$0.30
$0.33
Surprise
11.52%
38.68%
1.37%
-7.18%
-
Repligen News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.
Market closedNon-fractional
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Repligen stock?
Repligen (RGEN) has a market cap of $6.7B as of July 04, 2024.
What is the P/E ratio for Repligen stock?
The price to earnings (P/E) ratio for Repligen (RGEN) stock is 453.98 as of July 04, 2024.
Does Repligen stock pay dividends?
No, Repligen (RGEN) stock does not pay dividends to its shareholders as of July 04, 2024.
When is the next Repligen dividend payment date?
Repligen (RGEN) stock does not pay dividends to its shareholders.
What is the beta indicator for Repligen?
Repligen (RGEN) has a beta rating of 1.03. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.
Buy or sell Repligen stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.